## Anna Tosi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4736675/publications.pdf

Version: 2024-02-01

1307594 1199594 14 153 7 12 citations h-index g-index papers 14 14 14 165 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Clinical Cancer Research, 2022, 28, 308-317.	7.0	36
2	Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. Oncolmmunology, 2020, 9, 1777046.	4.6	24
3	Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncolmmunology, 2016, 5, e1199311.	4.6	21
4	The immune cell landscape of metastatic uveal melanoma correlates with overall survival. Journal of Experimental and Clinical Cancer Research, 2021, 40, 154.	8.6	19
5	Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. Cellular and Molecular Immunology, 2021, 18, 1197-1210.	10.5	14
6	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. Oncolmmunology, 2017, 6, e1313371.	4.6	11
7	A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. Neuro-Oncology, 2022, 24, 2146-2158.	1.2	9
8	162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial. Annals of Oncology, 2020, 31, S304-S305.	1.2	7
9	Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases Journal of Clinical Oncology, 2021, 39, 2021-2021.	1.6	5
10	Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Frontiers in Immunology, 2020, 11, 579894.	4.8	4
11	Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma. Biomedicines, 2021, 9, 1930.	3.2	2
12	129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial. Annals of Oncology, 2021, 32, S414.	1.2	1
13	281P Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases. Annals of Oncology, 2021, 32, S486-S487.	1.2	О
14	Immune microenvironment profiling of breast cancer brain metastases using multiplex immunofluorescence Journal of Clinical Oncology, 2020, 38, 2526-2526.	1.6	0